Article Details

Cytokinetics (NASDAQ:CYTK) Receives Buy Rating from HC Wainwright

Retrieved on: 2019-02-14 08:11:15

Tags for this article:

Click the tags to see associated articles and topics

Cytokinetics (NASDAQ:CYTK) Receives Buy Rating from HC Wainwright. View article details on hiswai:

Excerpt

<div><b>Two Sigma Investments</b> LP lifted its position in Cytokinetics by 41.0% during the fourth quarter. <b>Two Sigma Investments</b> LP now owns 45,242 shares of ...</div>

Article found on:

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo